Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Response seeks US OK for flu test:

This article was originally published in Clinica

Executive Summary

Response Biomedical has filed a US 510(k) application to market its rapid, point-of-care test for influenza A and influenza B. The qualitative test will run on the the Vancouver, Canada-based firm's RAMP platform and will be marketed and sold exclusively by 3M Health Care as the 3M Rapid Detection Flu A+B Test. It uses as specimens nasal wash, nasal swab, nasopharyngeal aspirate and nasopharyngeal swab.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048848

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel